336570 - WON Tech Co., Ltd.

336570 Summary

Medical Devices

Stock Price & Overview

₩4,905 +45 (+0.93%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩4,905 ≈ US$4 · Market cap ₩0.4tn (≈ $313m)

336570 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Revenue	156.8	115.3	115.6	81.5	51.1	30.0
Cost of Revenue	51.0	41.1	41.4	32.7	22.1	21.1
Gross Profit	105.8	74.1	74.3	48.8	28.9	8.9
Selling, General & Administrative	54.1	39.4	28.2	22.1	18.5	17.5
Operating Income	51.7	34.8	46.0	26.8	10.4	-8.6
Finance Income	5.2	6.7	2.0	1.0	0.5	0.2
Finance Costs	4.6	3.0	1.3	0.9	1.0	1.9
Pretax Income	46.2	38.6	47.8	17.8	9.3	-10.3
Income Tax Expense	10.9	9.5	9.0	4.4	-7.7	3.8
Net Income	35.2	29.1	38.8	13.4	17.0	-14.1
Total Comprehensive Income	35.5	29.4	39.0	13.2	16.7	-13.9

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	217.2	177.9	153.3	73.8	47.6	30.2
Current Assets	183.6	162.7	139.4	63.1	32.2	20.7
Cash & Cash Equivalents	32.5	32.8	12.2	6.3	2.4	2.8
Inventories	47.4	50.1	39.8	22.0	14.6	13.0
Trade Receivables	20.6	19.2	14.1	7.7	5.7	2.7
Non-current Assets	33.7	15.2	13.9	10.7	15.4	9.4
Property, Plant & Equipment	8.3	8.4	7.9	7.0	7.0	7.4
Intangible Assets	1.4	1.4	1.3	0.3	0.4	0.7
Total Liabilities	59.9	51.1	54.0	16.7	21.8	37.2
Current Liabilities	59.4	50.0	52.9	11.7	16.3	34.1
Non-current Liabilities	0.5	1.1	1.1	5.1	5.5	3.2
Total Equity	157.4	126.8	99.3	57.1	25.8	-7.1
Share Capital	9.0	8.9	8.8	8.8	3.2	2.4
Retained Earnings	104.8	74.1	49.4	10.6	-2.7	-19.7

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Cash from Operating Activities	51.1	14.9	26.0	14.8	6.1	0.4
Cash from Investing Activities	-39.9	7.8	-45.7	-6.8	-5.7	1.0
Purchase of Property, Plant & Equipment	1.2	1.8	2.1	0.5	0.5	0.2
Cash from Financing Activities	-11.7	-2.7	25.7	-4.1	-0.8	-0.4
Dividends Paid	4.4	4.4	0.0	—	—	—
Net Change in Cash	-0.3	20.7	5.9	3.8	-0.4	1.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	47.5	40.2	46.4	33.2	39.8	37.4	36.8	26.9	29.0	22.6
Cost of Revenue	17.6	11.6	15.3	10.6	11.8	13.4	13.5	9.6	12.0	6.0
Gross Profit	29.9	28.6	31.1	22.6	28.0	24.0	23.3	17.3	17.0	16.6
Selling, General & Administrative	—	17.4	18.9	15.0	10.7	9.5	9.5	9.9	10.0	9.9
Operating Income	11.1	11.2	12.2	7.6	17.3	14.6	13.8	7.3	7.0	6.6
Finance Income	23.5	3.3	1.9	1.1	1.0	1.2	3.5	0.5	1.2	1.5
Finance Costs	9.2	2.1	0.8	-0.0	2.8	1.0	0.6	1.2	0.6	0.6
Pretax Income	24.8	12.4	11.6	8.3	12.2	14.1	17.7	6.3	7.6	6.9
Income Tax Expense	9.4	1.9	5.3	0.4	3.0	2.2	15.2	-1.5	3.2	1.0
Net Income	15.4	10.4	6.2	7.9	9.2	11.9	14.0	4.8	4.4	5.9
Total Comprehensive Income	15.4	10.3	6.3	8.0	9.2	11.9	14.0	5.3	4.5	5.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	278.8	227.3	217.2	214.5	200.4	190.5	177.9	164.1	155.7	157.3
Current Assets	232.2	191.7	183.6	196.7	181.9	175.8	162.7	149.7	141.2	141.3
Cash & Cash Equivalents	33.1	24.1	32.5	26.2	27.3	45.8	32.8	13.2	10.3	10.5
Inventories	56.2	56.6	47.4	51.9	48.7	48.4	50.1	51.8	49.3	49.1
Trade Receivables	36.6	25.2	20.6	23.2	22.5	20.7	19.2	16.0	14.9	10.1
Non-current Assets	46.6	35.6	33.7	17.9	18.5	14.7	15.2	14.4	14.5	16.0
Property, Plant & Equipment	8.8	8.5	8.3	8.0	8.2	8.3	8.4	8.5	8.5	8.5
Intangible Assets	1.6	1.5	1.4	1.4	1.3	1.3	1.4	1.3	1.3	1.3
Total Liabilities	105.7	63.9	59.9	57.6	51.6	56.1	51.1	50.6	47.5	56.1
Current Liabilities	36.1	62.9	59.4	57.0	50.7	55.2	50.0	49.5	46.2	54.7
Non-current Liabilities	69.7	1.0	0.5	0.6	0.8	0.9	1.1	1.1	1.3	1.4
Total Equity	173.0	163.4	157.4	156.9	148.9	134.4	126.8	113.4	108.2	101.2
Share Capital	9.0	9.0	9.0	9.0	9.0	8.9	8.9	8.9	8.9	8.8
Retained Earnings	120.4	110.8	104.8	98.6	90.7	81.5	74.1	60.1	55.3	50.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-5.9	-7.5	19.1	10.6	8.1	13.3	13.3	7.1	-2.8	-2.7
Cash from Investing Activities	-24.3	-0.8	-6.6	-11.6	-21.5	-0.2	6.1	-4.1	4.5	1.3
Purchase of Property, Plant & Equipment	0.6	0.3	0.5	0.3	0.2	0.2	0.2	0.2	0.4	0.9
Cash from Financing Activities	39.2	-0.4	-6.4	-0.4	-4.6	-0.3	-0.2	-0.2	-2.0	-0.3
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	8.7	-8.4	6.3	-1.1	-18.4	12.8	19.7	2.9	-0.2	-1.7

Consolidated (CFS), from DART. 6 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

336570 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	156.8	+36.1%	+24.4%	+39.2%	—
Operating income	51.7	+48.6%	+24.5%	—	—
Net income	35.2	+21.0%	+38.0%	—	—
EPS	₩394	+21.0%	+38.0%	—	—
Operating cash flow	51.1	+242.6%	+51.2%	+160.7%	—
Shareholders' equity	157.4	+24.1%	+40.2%	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

336570 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	67.5%	64.3%	64.2%	59.9%	56.7%	29.7%
Operating margin	33.0%	30.2%	39.8%	32.8%	20.4%	-28.6%
Net margin	22.5%	25.3%	33.6%	16.4%	33.3%	-46.9%
Return on equity	24.8%	25.8%	49.7%	32.3%	181.6%	—
Return on assets	17.8%	17.6%	34.2%	22.1%	43.8%	-46.6%
Operating cash flow / revenue	32.6%	13.0%	22.4%	18.1%	11.9%	1.4%
Capex / revenue	0.8%	1.5%	1.8%	0.7%	1.0%	0.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 336570

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.